CRISM's ChemoSeed Platform Shows 72% Cancer Cell Kill Rate in Prostate Cancer Preclinical Studies
核心洞察
CRISM Therapeutics reported preclinical data showing its ChemoSeed drug delivery platform achieved 72% cancer cell kill rate with sustained docetaxel administration versus 65% with intermittent dosing.
The ChemoSeed platform enables sustained drug release over at least 28 days, potentially offering improved therapeutic efficacy through local and continuous chemotherapy delivery.
The company has secured a collaborative doctoral partnership with Ulster University to advance docetaxel-ChemoSeed development for personalized prostate cancer treatment.
CRISM Therapeutics Corp (搜索) announced significant preclinical findings demonstrating that its ChemoSeed drug delivery platform could substantially enhance docetaxel efficacy in prostate cancer treatment. The British Virgin Islands-based pharmaceutical company reported that sustained administration of docetaxel through the platform killed 72% of cancer cells compared to 65% achieved with intermittent dosing used in current standard care.
Enhanced Drug Delivery Performance
The ChemoSeed platform has successfully formulated docetaxel to achieve sustained drug release over a period of at least 28 days. This extended release profile represents a departure from conventional intermittent systemic administration approaches currently employed in prostate cancer chemotherapy.
Chief Executive Officer Andrew Webb emphasized the clinical significance of these findings, stating: "These developments represent a major step forward in our mission to improve outcomes for prostate cancer patients by leveraging our ChemoSeed drug delivery platform. The data clearly suggest that delivering chemotherapy locally and continuously, rather than intermittently and systemically, could provide a much-needed improvement in therapeutic efficacy."
Academic Partnership and Future Development
CRISM has been awarded a Department for the Economy collaborative doctoral partnership studentship in collaboration with Ulster University. This partnership will support the ongoing development of docetaxel-ChemoSeed and explore its application in personalized treatment approaches for prostate cancer patients.
The academic collaboration is expected to advance the platform's development toward clinical applications, focusing on optimizing the technology for individualized patient treatment strategies.
Market Response
Following the announcement, CRISM shares declined 7.0% to 10.23 pence in London trading on Tuesday afternoon, despite the positive preclinical data results.